We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
Read MoreHide Full Article
STERIS plc (STE - Free Report) is expected to release first-quarter fiscal 2025 results on Aug 6.
Earnings Surprise History
STE has a strong earnings surprise history. It beat on earnings in three of the trailing four quarters and missed the same once, the average surprise being 2.21%.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.41, in line with the Zacks Consensus Estimate.
Q1 Estimates
The Zacks Consensus Estimate for STERIS’ first-quarter fiscal 2025 revenues is pegged at $1.26 billion. This suggests a decrease of 1.7% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS of $2.03 indicates a year-over-year rise of 1.5%.
Estimate Revision Trend Ahead of Earnings
Estimates for STERIS’ fiscal first-quarter earnings have remained constant at $2.03 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major before the announcement.
Factors at Play
Healthcare
In the fiscal fourth quarter, growth across capital equipment, consumables, and services was robust, favored by positive price and high productivity. This helped the company to offset the macro challenges affecting demand in the other segments. Considering a persistent favorable pricing scenario and stabilizing macroeconomic issues, the Healthcare arm of STERIS is expected to have continued its strong momentum in the fiscal first quarter of 2025 as well.
We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS’ focus on getting back to normal lead times must have helped it in meeting customer demand.
Additionally, in the previous earnings call, the company announced a targeted restructuring plan, which includes restructuring the Healthcare Surgical Capital business in Europe as well as other actions, including impairment of an internally developed high-capacity X-ray accelerator, product rationalizations and facility consolidations. This is likely to have benefited the Healthcare segment in the fiscal first quarter.
Our model projects the segment’s revenues to improve 7.1% from the year-ago reported figure.
Applied Sterilization Technologies (AST)
Within the segment, the earlier-reported performances were adversely impacted by MedTech inventory destocking and the reduction of bioprocessing customer demand, both of which the company cites as short-term situations.
However, STE has been witnessing signs of recovery in the MedTech demand over the past couple of quarters, reflecting an improving procedure environment and the burndown of customer inventory in the United States. This impact might have lingered in the to-be-reported quarter as well.
During the fourth-quarter fiscal 2024 earnings call, the company projected no meaningful bioprocessing growth until the second half of fiscal 2025.
Per our model, the AST segment’s revenues for the fiscal first quarter are likely to increase 6.4% year over year.
Life Sciences
STERIS, in its fiscal 2025 guidance, has mentioned a full-year impact from the divestiture of the Controlled Environmental Services business within the Life Sciences segment. This might have contributed to its revenues in the to-be-reported quarter. The Life Sciences business segment has ended fiscal 2024 in line with the long-term expectations. We expect this trend to have been maintained throughout the to-be-reported quarter.
Our model projects the segment’s revenues for the fiscal first quarter to increase 5.8% year over year.
Dental
On May 31, 2024, STERIS completed selling its Dental segment to Peak Rock Capital for $787.5 million. It will receive up to an additional $12.5 million in contingent payments, payable if the Dental business achieves certain revenue targets in fiscal year 2025. The proceeds will be primarily used to repay debt. For the fiscal first quarter, the company is expected to report one month of sales from the Dental business.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
The company is set to release second-quarter 2024 results on Aug 5.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 79.17%. The Zacks Consensus Estimate for second-quarter EPS implies a surge of 266.7% from the year-ago quarter’s reported figure.
TransMedics Group (TMDX - Free Report) has an Earnings ESP of +23.54% and a Zacks Rank #3 at present. The company is set to release second-quarter 2024 results on Aug 1.
TransMedics has an expected sales growth rate of 15.78% for 2024. TMDX beat on earnings in two of the trailing four quarters and missed in the other two, the average surprise being 9.93%.
Tenet Healthcare(THC - Free Report) has an Earnings ESP of +4.11% and a Zacks Rank #2 at present. The company is set to release second-quarter 2024 results on Jul 24.
THC has an expected long-term earnings growth rate of 12.5% compared to the industry’s 11.9%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 56.50%.
Image: Bigstock
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
STERIS plc (STE - Free Report) is expected to release first-quarter fiscal 2025 results on Aug 6.
Earnings Surprise History
STE has a strong earnings surprise history. It beat on earnings in three of the trailing four quarters and missed the same once, the average surprise being 2.21%.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.41, in line with the Zacks Consensus Estimate.
Q1 Estimates
The Zacks Consensus Estimate for STERIS’ first-quarter fiscal 2025 revenues is pegged at $1.26 billion. This suggests a decrease of 1.7% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS of $2.03 indicates a year-over-year rise of 1.5%.
Estimate Revision Trend Ahead of Earnings
Estimates for STERIS’ fiscal first-quarter earnings have remained constant at $2.03 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major before the announcement.
Factors at Play
Healthcare
In the fiscal fourth quarter, growth across capital equipment, consumables, and services was robust, favored by positive price and high productivity. This helped the company to offset the macro challenges affecting demand in the other segments. Considering a persistent favorable pricing scenario and stabilizing macroeconomic issues, the Healthcare arm of STERIS is expected to have continued its strong momentum in the fiscal first quarter of 2025 as well.
We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS’ focus on getting back to normal lead times must have helped it in meeting customer demand.
Additionally, in the previous earnings call, the company announced a targeted restructuring plan, which includes restructuring the Healthcare Surgical Capital business in Europe as well as other actions, including impairment of an internally developed high-capacity X-ray accelerator, product rationalizations and facility consolidations. This is likely to have benefited the Healthcare segment in the fiscal first quarter.
Our model projects the segment’s revenues to improve 7.1% from the year-ago reported figure.
Applied Sterilization Technologies (AST)
Within the segment, the earlier-reported performances were adversely impacted by MedTech inventory destocking and the reduction of bioprocessing customer demand, both of which the company cites as short-term situations.
However, STE has been witnessing signs of recovery in the MedTech demand over the past couple of quarters, reflecting an improving procedure environment and the burndown of customer inventory in the United States. This impact might have lingered in the to-be-reported quarter as well.
During the fourth-quarter fiscal 2024 earnings call, the company projected no meaningful bioprocessing growth until the second half of fiscal 2025.
Per our model, the AST segment’s revenues for the fiscal first quarter are likely to increase 6.4% year over year.
Life Sciences
STERIS, in its fiscal 2025 guidance, has mentioned a full-year impact from the divestiture of the Controlled Environmental Services business within the Life Sciences segment. This might have contributed to its revenues in the to-be-reported quarter. The Life Sciences business segment has ended fiscal 2024 in line with the long-term expectations. We expect this trend to have been maintained throughout the to-be-reported quarter.
STERIS plc Price and EPS Surprise
STERIS plc price-eps-surprise | STERIS plc Quote
Our model projects the segment’s revenues for the fiscal first quarter to increase 5.8% year over year.
Dental
On May 31, 2024, STERIS completed selling its Dental segment to Peak Rock Capital for $787.5 million. It will receive up to an additional $12.5 million in contingent payments, payable if the Dental business achieves certain revenue targets in fiscal year 2025. The proceeds will be primarily used to repay debt. For the fiscal first quarter, the company is expected to report one month of sales from the Dental business.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Hims & Hers Health(HIMS - Free Report) has an Earnings ESP of +19.28% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is set to release second-quarter 2024 results on Aug 5.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 79.17%. The Zacks Consensus Estimate for second-quarter EPS implies a surge of 266.7% from the year-ago quarter’s reported figure.
TransMedics Group (TMDX - Free Report) has an Earnings ESP of +23.54% and a Zacks Rank #3 at present. The company is set to release second-quarter 2024 results on Aug 1.
TransMedics has an expected sales growth rate of 15.78% for 2024. TMDX beat on earnings in two of the trailing four quarters and missed in the other two, the average surprise being 9.93%.
Tenet Healthcare(THC - Free Report) has an Earnings ESP of +4.11% and a Zacks Rank #2 at present. The company is set to release second-quarter 2024 results on Jul 24.
THC has an expected long-term earnings growth rate of 12.5% compared to the industry’s 11.9%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 56.50%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.